Good news for treating staph....BD
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., announced that the investigational antibiotic ceftobiprole was as effective as commonly used combination therapy in treating patients with complicated skin infections caused by a broad spectrum of bacteria. Ceftobiprole also was found to clinically cure more than 90% of patients who had infections caused by Staphylococcus aureus (S. aureus), including patients with complicated skin infections due to PVL- positive methicillin-resistant S. aureus (MRSA). These new data were presented in two posters at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
0 comments :
Post a Comment